Driving clarity
in clinical development

Talk to us about where your study is today

Every clinical trial is a chain of high-stakes decisions.

Unlearn can help at any point in your study. Digital twins, data, and AI strengthen each one — so trial teams can commit with confidence, and evidence compounds from one decision to the next.

Explore every entry point

AI Regulatory Strategy Expertise

READOUT INFORMS THE NEXT DESIGN

Design a smaller study from the start

A Phase 1/2 study at the design stage

Sample size reduction
locked into study design

Total cost savings for a Phase 1/2 study

Pressure-test your design ↗

See what your next study could save

A completed Phase 3 study, re-analyzed with digital twins

Fewer participants at the same power

Lower cost

Unlock more from your data ↗

Reduce the control arm and enroll faster

A completed Phase 3 study, re-analyzed with digital twins

Smaller control arm

Enrollment time saved (months)

View AbbVie Case Study ↗

Strengthen single-arm evidence

A Phase 3 study, re-analyzed as if it had no control arm

Closer to the randomized result than PSM

Statistical power on Total Functional Capacity raised from 70% with PSM to 86%

Learn more about digital twins in single-arm trials ↗

Why leading sponsors choose Unlearn

“Working with Unlearn to mine their extensive, well-curated database through the use of the ALS DTG will enable us to explore smarter designs and make confident and informed decisions as we plan our Phase 1/2 trial. Ultimately, these insights can help us to move faster for people living with ALS who are waiting for new treatment options."

Eric Green, M.D., Ph.D., co-founder and CEO of Trace Neuroscience

See Press Release

“The ecosystem at the moment doesn’t sustain the way we’ve been doing it traditionally. And (Unlearn) is at the leading edge of this thinking.”

Kasper Roet, founder and CEO of QurAlis

View Presentation

"The collaboration with Unlearn and the resulting data further increases our confidence in our pioneering approach towards achieving symptomatic relief and disease modification in Alzheimer’s. This will support our efforts to advance an optimized second-generation therapy. Digital twins offer a new lens for interpreting biomarker trends over time—especially in early-stage trials where every data point matters."

Gerard Griffioen, Ph.D., CSO of remynd

See Press Release